News

China has become the world's second largest pharmaceutical consumer market

  • Author:Jane
  • Source:Xinhua News Agency
  • Release on :2017-07-13
CFDA Deputy Director Wu Zhen 12, said that after years of development, China has become the world's second largest pharmaceutical consumer market, the largest export of bulk drugs.

Wu Zhen held in the day of the 2017 developing countries drug quality management seminar classes said that China's existing nearly 5,000 raw materials and pharmaceutical companies, pharmaceutical manufacturing annual main business income of more than 2.5 trillion yuan, of which Nearly 50 pharmaceutical companies through the European and American certification or inspection, pharmaceutical manufacturing exports more than 13.5 billion US dollars, indicating that China's pharmaceutical industry already has the rest of the world to provide safe and reliable pharmaceutical products.

In 2015, the Chinese female drug scientist Tu Yo Yo won the Nobel Prize in Physiology or Medicine. Wu Zhen pointed out that China's pharmaceutical industry is to contribute to the development of innovative drugs around the world, in the field of global disease prevention and health protection play an active role. As the World Health Organization recommended first-line antimalarials, artemisinin in the world, especially in developing countries to save the lives of millions of people, this discovery is known as "the second half of the 20th century the greatest medical pioneering."

Wu Zhen also pointed out that China still has some problems in the pharmaceutical economy and drug regulation, such as the imbalance between the areas of drug research and development, production, circulation and use, and the incompatibility between the areas of drug regulation. In addition, with the rapid development of science and technology, drugs in research and development, production and use of diversity and complexity.

To effectively speed up the speed of drug review and approval to solve the backlog of drug registration, Food and Drug Administration this year in the drug review and approval system reform to take further measures to achieve good results. Wu Zhen pointed out that the Food and Drug Administration has redefined the definition and classification of new drugs, clear the generic drugs must be consistent with the original drug quality evaluation criteria, the establishment of a clinical efficacy-oriented drug review system, Technology, based on the quality, focus on drug clinical trial results to ensure the clinical efficacy of listed drugs.